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and Lynn B Panton1Abstract
The effects of multi-ingredient performance supplements (MIPS) on perceived soreness, strength, flexibility and
vertical jump performance following eccentric exercise are unknown. The purpose of this study was to determine
the impact of MIPS (NO-Shotgun®) pre-loaded 4 weeks prior to a single bout of downhill running (DHR) on muscle
soreness and performance. Trained male runners (n = 20) were stratified by VO2max, strength, and lean mass
into two groups; MIPS (n = 10) ingested one serving daily of NO-Shotgun® for 28 days and 30 min prior to all
post-testing visits, Control (CON; n = 10) consumed an isocaloric maltodextrin placebo in an identical manner as
MIPS. Perceived soreness and performance measurements (strength, flexibility, and jump height) were tested on
6 occasions; 28 days prior to DHR, immediately before DHR (PRE), immediately post (POST) DHR, 24, 48, and 72 hr
post-DHR. Perceived soreness significantly increased (p < 0.05) post DHR compared to PRE at all time-points, with
no difference between groups. Creatine kinase (CK) and lactate dehydrogenase (LDH) increased over time (p < 0.001)
with no group x time interactions (p = 0.236 and p = 0.535, respectively). Significant time effects were measured for
strength (p = 0.001), flexibility (p = 0.025) and vertical jump (p < 0.001). There were no group x time interactions for any
performance measurements. Consumption of MIPS for 4 weeks prior to a single bout of DHR did not affect perceived
soreness, muscle damage, strength, flexibility, or jump performance compared to an isocaloric placebo in trained male
runners following a single bout of DHR.
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Exercise induced muscle damage (EIMD) from unaccus-
tomed bouts of eccentric or strenuous exercise has been
well documented [1-4]. EIMD promotes an unbalanced
ratio of protein breakdown to protein synthesis and is
associated with increased muscle soreness, decrements
in strength, and impaired muscle function for several
days post-exercise [5]. Muscle damage induced by strenu-
ous or unaccustomed downhill running (DHR) initiates
biochemical and skeletal muscle morphology changes
indicated by localized edema, increased circulating* Correspondence: mormsbee@fsu.edu
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unless otherwise stated.inflammatory markers (cytokines and leukocytes), and
increases in indirect markers of muscle damage (creatine
kinase (CK), lactate dehydrogenase (LDH)) [3,6].
In parallel with elevated markers of tissue damage fol-
lowing eccentric exercise are decrements in performance
measures, including muscular power, maximal contractile
force (eccentric, concentric, isometric), and endurance
performance [2,7,8]. Previous studies have demonstrated a
positive impact on recovery from EIMD through supple-
mentation with whey protein isolate [5], branched-chain
amino acids (BCAAs: leucine, isoleucine, and valine)
[9,10], leucine only [2], creatine [11,12], and caffeine
[13,14]. However, little is known about the effects of multi-
ingredient performance supplements (MIPS) [i.e. common
MIPS components: protein, BCAAs, creatine, beta-alanine,
caffeine, and l-arginine] on the attenuation of muscle dam-
age and repair after EIMD from DHR. Multiple studiesal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Ormsbee et al. Journal of the International Society of Sports Nutrition  (2015) 12:2 Page 2 of 9have demonstrated beneficial effects following an identical
28-day, pre-exercise supplementation protocol [15-17].
While the improved strength and body composition
variables from MIPS supplementation in these studies
are promising, a resistance training protocol was used.
However, the significantly increased muscle mass and
strength gains with MIPS supplementation suggests
the MIPS may have elicited improvements via specific
ingredients included in the MIPS. Specifically, increased
muscle protein synthesis and recovery (i.e. protein,
BCAAs, leucine), hydrogen ion buffering (i.e. beta-alanine),
ATP resynthesis (i.e. creatine), and/or improved CNS
stimulation (i.e. caffeine) are plausible mechanisms of
action.
While the aforementioned pre-exercise MIPS supple-
mentation studies are promising [15-17], due to the use
of a resistance training protocol, assumptions must be
made to draw conclusions about the effects of MIPS on
the attenuation of EIMD following a DHR in an endur-
ance population. Therefore, the purpose of this study
was to determine the impact of MIPS, pre-loaded 4
weeks prior to- and for 72 hr following a single bout of
DHR on muscle damage, soreness, and performance
during recovery. We hypothesized that this supplemen-
tation protocol would decrease ratings of perceived sore-
ness, improve biochemical markers of muscle damage
(i.e. CK and LDH), improve muscle performance of
isokinetic and isometric strength, range of motion (ROM),
and jump performance greater than an isocaloric pla-
cebo in endurance-trained male runners for up to 72 hr
post-DHR.
Methods
Participants
Twenty healthy, male endurance-trained runners (max-
imal oxygen uptake (VO2max) ≥ 55 ml/kg/min and an
average 20 miles/week of running), ages 18–50 years
were recruited to participate in this study (Table 1).
Participants were excluded if they had existing diseases
(e.g. cardiovascular disease), musculoskeletal disorders,
any history of leg injury or any other medical conditionTable 1 Participant characteristics (N = 20)
MIPS (n = 10) CON (n = 10)
Age (yrs) 24 ± 5 30 ± 10
Height (cm) 178.3 ± 5.6 181.9 ± 7.5
Body Mass (kg) 72.4 ± 8.3 74.4 ± 6.3
Body Fat (%) 9.2 ± 2.6 10.3 ± 3.1
VO2max (ml/kg/min) 61.7 ± 5.3 61.4 ± 4.9
Values are expressed as mean ± SD.
MIPS: Multi-Ingredient Performance Supplement; CON: Control Carbohydrate
Placebo; VO2max: Maximal Oxygen Uptake.that would be exacerbated by a single bout of DHR, or
the regular use of any anti-inflammatory drugs. Partici-
pants who were consuming any other dietary or ergo-
genic supplements were instructed to immediately stop
consumption and complete a 4-week washout period
before participating in the study (one participant repor-
ted use of a generic over-the-counter multivitamin sup-
plement, no other supplement use was reported). All
procedures involving human subjects were approved by
the Florida State University Human Subjects Institutional
Review Board, and written informed consent was obtained
prior to participation. Throughout the study, all partici-
pants maintained their habitual diet, and were given 24-hr
dietary food logs to record their meals the day prior to
baseline testing and asked to replicate these meals before
all other laboratory visits. Participants ate their last meal
at least 6 hr prior to testing and consumed a commercial
Chocolate Chip Clif Bar® (240 kcals) 3 hr prior to testing
and at least 3 hr from their last meal.
Treatment
The study was a placebo-controlled, double blind proto-
col with two groups. After baseline testing participants
were stratified by VO2max, isometric voluntary contrac-
tion strength (60°), and lean mass and assigned to either
MIPS (n = 10) or CON (n = 10). MIPS consumed one
serving (21 g) of NO-Shotgun® (~72 kcals; 18 g protein;
9.7 g protein hydrolysate matrix including BCAAs; 8.06
g muscle volumizing and power/speed/strength matrix
that includes multiple forms of creatine and beta alanine;
376 mg of Redline®energy matrix including caffeine;
Vital Pharmaceuticals, Inc., Davie, FL) once per day for 4
weeks prior to the DHR and 30 min prior to all post-
testing visits (3 days) with 355 - 473 ml of water. CON
consumed one serving (21 g) of an isocaloric, flavor-
matched placebo beverage (maltodextrin) once per day for
4 weeks prior to the DHR, as well as 30 min prior to all
post-testing visits. All participants received their supple-
ment in identical commercially labeled containers after
baseline testing. Participants consumed either MIPS or
CON 30 min prior to exercise on all exercise training
days, or first thing in the morning on non-training days.
Empty containers were collected to verify compliance
from all participants.
Experimental overview
Participants reported to the laboratory on 7 different
occasions (Figure 1). The first visit included a review of
the informed consent document, distribution of the
Chocolate Chip Clif Bar®, as well as the measurement of
anthropometric values. The second laboratory visit was
no later than 1 week from the first visit and was used as
the baseline/inclusion testing for participation in the
study, including VO2max determination. Subsequent to
Figure 1 Study timeline. VAS: Visual Analog Scale, VO2max: Maximal Oxygen Uptake, ROM: Range of Motion.
AMulti-Ingredient Performance
Supplement (MIPS) or Control (CON) consumed once daily from Visit 2 up to 1 day prior to Visit 4 (30 min prior to exercise on training days and
immediately upon waking on non-training days); *MIPS or CON consumed 30 min prior to visits 4, 5, 6, and 7.
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mill running protocol was employed to determine
VO2max using a motor driven treadmill (Woodway®,
Waukesha, WI, USA). Expired air was measured breath-
by-breath by indirect calorimetry using a metabolic
measurement system (Parvomedics Truemax® 2400,
Consentius Technologies, Sandy, UT, USA). Prior to the
beginning of each test, the gas analyzer was calibrated
using ambient air and a gas of a known composition
containing 20.9% O2 and 4% CO2. The turbine flow-
meter was calibrated using a 3-L syringe (Hans Rudolph,
Inc., Kansas City, MO, USA).The participant began by
walking for 5 min at 3 mph then the speed was in-
creased to 5.5 mph at a 0% grade for 2 min (stage 1).
Upon completion of the first stage the speed was in-
creased 1 mph every 2 min until the participant reached
the speed of 9.5 mph (stage 5). After the completion of
stage 5 the participant maintained a running speed of
9.5 mph and the grade was increased by 2% every 2 min
until the participant reached volitional fatigue. Heart
rate was monitored using a heart rate monitor (Polar™,
Lake Success, NY, USA). Ratings of perceived exertion
(RPE) and heart rate were recorded at the end of each
stage, as well as when participants reached volitional ex-
haustion, or requested to stop the test. The test was con-
sidered to be a maximal test under 2 conditions: 1) If the
participants’ VO2 reached a plateau for more than 1 stage
(2 min intervals) while intensity continued to increase or
2) Participants exhibited 2 of the following secondary cri-
teria: RPE ≥ 19, respiratory exchange ratio (RER) ≥ 1.1, or
a heart rate within 10 beats/min of the theoretical agepredicted maximum heart rate (220 – age). The re-
searchers provided verbal encouragement during the test
to ensure maximal effort.
Upon completion of baseline testing the participants
were given instructions on supplementation and instruc-
ted to maintain their normal dietary and training patterns
for the next 28 days during supplementation. Approxi-
mately 3 weeks from baseline testing participants returned
to the laboratory under the same pretesting conditions as
baseline to perform a VO2max test to determine their in-
tensity (75% of VO2max) during the DHR.
A 10 ml venous blood sample was collected and per-
ceived muscle soreness, jump height, isokinetic and iso-
metric strength, and ROM were measured, respectively,
during 5 different laboratory visits: baseline (28 days before
DHR), immediately before the DHR (PRE), immediately
after the DHR (POST), and 24, 48, and 72 hr post-DHR.
After the blood draw and muscle soreness was measured,
participants walked for 5 min at 3 mph on a motorized
treadmill to warm-up prior to any performance measure-
ments (the DHR was only performed during visit 4; See
Figure 1). Prior to these visits participants consumed their
commercial Chocolate Chip Clif Bar® (given during visit 1)
3 hr before testing and replicated their 24 hr dietary food
logs. Participants were asked to refrain from physical ac-
tivity 48 hr and caffeine, alcohol, and pain medication (i.e.
ibuprofen) 24 hr prior to all laboratory testing visits.
Measures
Muscle soreness was measured via a visual analog scale
(0–100 mm). Participants rated their level of soreness of
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ceps femoris, gastrocnemius, and gluteus maximus on
the right leg by drawing an intersecting line across a
continuum line extending from 0 mm (0 = no soreness)
to 100 mm (100 = extreme soreness). To help quantify
pain, an algometer (Force Ten™ Wagner Instruments,
Greenwich, CT, USA) was used with an application of
4 kg of pressure. The midline of the muscle was deter-
mined using a tape measure and the algometer was
placed at this point with the application of the 4 kg of
pressure.
Jump height was assessed using a Vertec vertical
jump system (Perform Better, Cranston, RI), recording
the best of 5 attempts. The squat jump test was used
to assess dynamic explosive force production of the
leg extensors. With no restriction on knee angle dur-
ing the eccentric phase of the knee flexion, partici-
pants were instructed to bend down with their knees
shoulder width apart and explosively jump, reaching
their hand as high as possible during the peak height
of the jump to shift the tabs at the top of the Vertec
bar. Participants completed 5 jumps with 30 seconds of
rest between each jump with the highest measure re-
corded for analysis.
Isokinetic (5 repetitions, 180°/sec unilateral knee/exten-
sion flexion) and isometric (3 repetitions/5 second rest,
60° isometric knee extension/flexion) strength of the dom-
inant leg were determined using the Biodex System 3
(Biodex Medical Systems, Shirley, New York) exercise
dynamometer. Each participant was placed in the upright-
seated position in the Biodex system, and the seat height
and position were adjusted in order to align the instru-
ment’s axis of rotation with the participant’s knee. Once
positioned correctly and secured, ROM was determined
along with the weight of the limb. The dominant leg was
used for all Biodex testing. Participants were instructed to
cross their arms over their chests without holding the
restraints or handles. The first test was an isokinetic
180°/sec unilateral knee/extension flexion. Five repeti-
tions of consecutive maximal extension and flexion
concentric contractions were performed. Sixty seconds
following the isokinetic test, a 60° isometric knee ex-
tension/flexion test was performed. The test involved
3 alternating maximal extension and flexion exertions
against an immovable arm, with 5 second rest periods
between exertions. Continuous verbal encouragement
was provided by the research team throughout the
duration of all tests. Participants were allowed to view
the data reporting screen and all values as they were
recorded. The peak torque of the isokinetic and iso-
metric tests for the quadriceps and hamstrings were
recorded for later analysis.
Range of motion (ROM) was measured by sit-and-
reach assessment using standard testing procedures [18](Figure Finder Flex Tester® box; Novel Products, Inc.,
Rockton, IL, USA). The best of 3 trials was recorded as
the final value used for statistical analysis.
Height and weight were measured via the use of a
wall-mounted SECA 216 stadiometer and a digital scale
(SECA, Hamburg, Germany), respectively. All measure-
ments were taken without shoes and wearing minimal
clothing (e.g. running shorts). Body composition was
measured non-invasively using the sum of 3 skinfold
measurements (chest, abdomen, and thigh), all taken by
the same technician, that were used to calculate body fat
percentage [19].
Blood (10 mL) was collected via venipuncture of the
antecubital vein at baseline testing, PRE, POST, 24, 48,
and 72 hr after the DHR. Following the blood collection,
serum (BD Vacutainer, no coagulant) was allowed to
clot and centrifuged at 3500 RPM at 4°C for 15 min
(Sorvall ST16R Multispeed Centrifuge; Thermo Electron
Corporation, Needham Heights, Massachusetts). Aliquots
(300 μL) were then transferred into microtubes and
immediately frozen at −80°C for later batch analysis.
Serum CK activity and LDH were analyzed in duplicate
using commercially labeled assay kits (BioAssay Systems,
EnzyChrom).Downhill running protocol
Prior to the DHR during visit 4, participants began by
warming up for 5 min walking on a level grade at 3 mph.
The treadmill grade was then lowered to -5% grade. Par-
ticipants ran continuously for 60 min at a speed eliciting
75% of their VO2max on a level grade (determined during
visit 3) [18]. Heart rate and RPE were monitored continu-
ously and recorded every 10 min during the DHR (data
not shown).Statistical analysis
Sample size was determined using the data from the
study by Hoffman et al. [8]. Using an alpha level of 0.05
and power of 80% an effect size of 0.88 was determined.
Therefore, a total of 10 participants per group were
needed. Participant characteristics and baseline data be-
tween groups were analyzed using one-way analysis of
variance (ANOVA). Baseline data were also compared to
PRE data (after 4 weeks of MIPS or CON) to see if
supplementation affected measured parameters by using
a 2×2 repeated measures ANOVA. The DHR data were
analyzed using a 2 × 5 (group: MIPS or CON × time:
PRE, POST, 24, 48, 72 hr) ANOVA with repeated
measures. A LSD post-hoc test was used to examine
pairwise differences if there were significant main effects.
Greenhouse-Geisser analysis was used if the Mauchly’s
Test of Sphericity was violated. Significance was set at
p < 0.05. SPSS version 21.0 (SPSS Inc, Cary, NC) was
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means ± standard deviations.Results
There were no significant differences between groups at
baseline (Table 1) and no differences were observed for
any variable when baseline data were compared to PRE
data, with the exception of a significant time effect for
an increase in flexibility and vertical jump (p = 0.005 and
p = 0.006, respectively). Supplement compliance was re-
ported to be 100% as verified by collection of empty sup-
plement containers and questioning.Delayed onset muscle soreness
There were no significant differences in perceived
muscle soreness between groups at any time point for
any of the muscle groups tested (Table 2). There were,
however, significant main time effects for the rectus
femoris (p < 0.001), vastus medialis (p = 0.002), vastus
lateralis, (p = 0.001), biceps femoris (p = 0.007), and glu-
teus maximus (p = 0.014). Perceived muscle soreness was
reported to be significantly (p < 0.05) greater than PRE
in the rectus femoris (24, 48, and 72 hr), vastus medialis
(POST, 24 hr), vastus lateralis (POST, 24, 48, and 72 hr),
biceps femoris (POST, 24, 48, and 72 hr, and the gluteus
maximus (POST, 24, 48 hr) of the right leg in both
groups. The mean of all muscle soreness was reported to
be significantly greater (p < 0.05) than PRE at all time-Table 2 Perceived muscle soreness of the right leg
Variable Group Pre DHR (day 0) PO
Gastrocnemius MIPS (n = 9) 15.7 ± 20.7 18.
CON (n = 10) 9.3 ± 9.7 10.
Rectus Femoris* MIPS (n = 9) 11.2 ± 18.5 14.
CON (n = 10) 10.3 ± 9.0 14.
Vastus Lateralis* MIPS (n = 8) 6.6 ± 10.6 16.
CON (n = 10) 8.2 ± 5.8 14.
Vastus Medialis* MIPS (n = 8) 11.0 ± 14.3 24.
CON (n = 10) 12.6 ± 10.0 16.
Biceps Femoris* MIPS (n = 9) 7.3 ± 12.8 9.4
CON (n = 10) 5.0 ± 4.0 10.
Gluteus Maximus* MIPS (n = 9) 6.5 ± 10.2 13.
CON (n = 10) 6.3 ± 6.5 9.0
Mean Muscle Soreness* MIPS (n = 7) 66.3 ± 88.1 110
CON (n = 8) 55.3 ± 40.3 74.
Values are expressed as mean ± SD. MIPS: Multi-Ingredient Performance Supplemen
*p < 0.05, significant time effect.
ap < 0.05, significantly different from Pre.
bp < 0.05, significantly from POST.
cp < 0.05, significantly different from 24 hr.
dp < 0.05, significantly from 48 hr.
ep < 0.05, significantly different from 72 hr.points (POST, 24, 48, and 72 hr), with no difference
between groups.Performance measurements
There was no significant difference between maximal
isometric voluntary contraction strength, maximal iso-
kinetic strength, vertical jump, and ROM, and between
baseline and PRE for MIPS and CON (data not shown).
However, there was a significant time effect for an in-
crease in ROM (p = 0.005) and vertical jump (p = 0.006)
from baseline to PRE in both groups.
There were no significant group × time interactions
for the MIPS and the CON across time for any of the
performance measures (Table 3). There were, however,
significant time effects for maximal voluntary isomet-
ric contraction for extension (p = 0.001) and flexion
(p = 0.013) strength, maximal isokinetic flexion strength
(p = 0.001), flexibility (p = 0.025), and vertical jump height
(p < 0.001).Maximal oxygen uptake
There was a significant group × time interaction for
VO2max between baseline and 1 week prior to the DHR
(MIPS: 61.7 ± 5.3 to 63.3 ± 5.8 ml/kg/min; CON: 61.4 ±
4.9 to 60.4 ± 5.9 ml/kg/min). When evaluating the within
group differences, there were no significant differences
in VO2max; however, MIPS had an increase approaching
significance (p = 0.06) while CON had a non-significantST (day 0) 24 hr post 48 hr post 72 hr post
3 ± 19.8 17.7 ± 21.4 12.8 ± 21.1c 13.1 ± 17.4c
6 ± 10.6 16.1 ± 13.1 11.4 ± 9.7c 13.0 ± 14.9c
7 ± 14.5 19.4 ± 15.0abde 14.7 ± 15.5e 8.5 ± 10.1b
7 ± 9.6 26.1 ± 18.0abde 15.8 ± 14.6e 13.5 ± 11.1b
0 ± 15.3a 21.8 ± 19.6ab 17.2 ± 17.3a 16.7 ± 21.2a
0 ± 11.2a 19.9 ± 15.6ab 19.4 ± 15.7a 11.1 ± 7.9a
6 ± 19.7a 34.3 ± 24.8abde 20.7 ± 24.8 16.6 ± 20.9
6 ± 12.3a 26.5 ± 21.0abde 21.4 ± 16.9 17.0 ± 13.8
5 ± 11.7a 21.5 ± 17.5abe 11.7 ± 17.8a 12.1 ± 14.6a
2 ± 9.4a 19.2 ± 18.9abe 13.3 ± 12.0a 7.9 ± 9.8a
6 ± 16.9a 20.2 ± 21.3a 13.2 ± 19.3a 8.5 ± 14.5
± 8.6a 10.8 ± 11.7a 6.6 ± 6.7a 8.2 ± 7.7
.9 ± 97.1a 153.3 ± 104.4abde 105.9 ± 106.6a 88.6 ± 100.6
1 ± 58.6a 114.6 ± 90.5abde 86.6 ± 73.3a 74.4 ± 63.2
t; CON: Control Carbohydrate Placebo.
Table 3 Performance measurements (n = 10 for MIPS and CON)
Variable Group Pre DHR (day 0) POST (day 0) 24 hr post 48 hr post 72 hr post
MVC Extension (60°) (N · m)* MIPS 207 ± 52 185 ± 40 199 ± 58b 210 ± 49b 217 ± 37bcd
CON 196 ± 58 184 ± 50 200 ± 58b 205 ± 59b 221 ± 64bcd
MVC Flexion (60°) (N · m)* MIPS 116 ± 36b 107 ± 31 109 ± 33b 117 ± 34b 118 ± 26bc
CON 109 ± 30b 99 ± 27 108 ± 30b 108 ± 28b 113 ± 33bc
Maximal Isokinetic Extension (180°/sec) (N · m)* MIPS 149 ± 22c 149 ± 23 140 ± 20a 151 ± 19c 152 ± 18c
CON 143 ± 27c 139 ± 18 136 ± 26a 140 ± 28c 145 ± 32c
Maximal Isokinetic Flexion (180°/sec) (N · m)* MIPS 78 ± 17 77 ± 19 78 ± 16 81 ± 17ab 81 ± 18ab
CON 70 ± 22 72 ± 19 79 ± 17 80 ± 20ab 82 ± 23ab
ROM (cm)* MIPS 25.1 ± 11.7c 25.8 ± 11.3c 23.6 ± 12.6a 25.7 ± 11.4c 25.5 ± 11.3c
CON 20.3 ± 10.6c 21.2 ± 10.4c 19.6 ± 10.5 19.3 ± 10.1 20.1 ± 10.4c
Vertical Jump (cm)* MIPS 51.3 ± 7.3c 52.3 ± 6.6c 50.0 ± 18.0 50.0 ± 6.6bc 51.0 ± 7.1cd
CON 50.0 ± 14.7c 50.2 ± 14.2c 47.4 ± 13.4 49.0 ± 13.9bc 50.0 ± 13.7cd
Values are expressed as mean ± SD.
MIPS: Multi-Ingredient Performance Supplement; CON: Control Carbohydrate Placebo; MVC: Maximal Voluntary Isometric Contraction; ROM: Range of Motion; DHR:
Downhill Run; POST: Immediately Post-DHR.
*p < 0.05, significant time effect.
ap < 0.05, significantly different from Pre.
bp < 0.05, significantly from POST.
cp < 0.05, significantly different from 24 hr.
dp < 0.05, significantly from 48 hr.
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the Parvomedics metabolic cart was an average of 0.4%.
Muscle damage markers
There were no significant group × time interactions for
either CK or LDH from baseline to PRE (p = 0.056 and
p = 0.392, respectively); however a significant time ef-
fect was observed for CK (p = 0.021) but not for LDH
(p = 0.079). There was a significant time effect for both
CK and LDH from PRE to 72 hr post-DHR (p < 0.001)
(See Figures 2 and 3); however no group x time effect for
CK or LDH was observed (p = 0.236 and p = 0.535, re-
spectively). When data from both groups were collapsed,Figure 2 Creatine Kinase measured in serum. Values are
expressed as mean ± SD creatine kinase levels. MIPS: Multi-Ingredient
Performance Supplement; CON: Control Carbohydrate Placebo; Pre,
immediately before downhill run; POST, immediately post-downhill
run; 24 hr, 24 hr post-downhill run; 48 hr, 48 hr post-downhill run;
72 hr, 72 hr post-downhill run. *p < 0.05, significant time effect.CK levels were significantly elevated from POST to 48 hr
when compared to PRE values. LDH levels were signifi-
cantly elevated POST before returning to PRE values at
24 hr.
Discussion
The main findings of this study were that consumption
of MIPS for 4 weeks prior to a single bout of DHR did
not attenuate the changes of ratings of perceived sore-
ness, isokinetic or isometric strength, jump performance,
or ROM greater than an isocaloric placebo (CON) in
highly trained male runners for up to 72 hr post-Figure 3 Lactate Dehydrogenase measured in serum. Values
are expressed as mean ± SD lactate dehydrogenase levels. MIPS:
Multi-Ingredient Performance Supplement; CON: Control Carbohydrate
Placebo; Pre, immediately before downhill run; POST, immediately
post-downhill run; 24 hr, 24 hr post-downhill run; 48 hr, 48 hr
post-downhill run; 72 hr, 72 hr post-downhill run. *p < 0.05, significant
time effect.
Ormsbee et al. Journal of the International Society of Sports Nutrition  (2015) 12:2 Page 7 of 9exercise. Therefore, we reject our hypothesis that the
MIPS would decrease ratings of perceived soreness, im-
prove biochemical markers of muscle damage (i.e. CK
and LDH), improve muscle performance of isokinetic
and isometric strength, range of motion (ROM), and
jump performance greater than an isocaloric placebo in
endurance-trained male runners for up to 72 hr post-
DHR.
Delayed onset muscle soreness
Delayed onset muscle soreness (DOMS) generally de-
velops between 24-48 hr after exercise, peaks at 24-72
hr, and subsides 5-7 days post-exercise [20]. Two days
after DHR, tenderness, measured by a pressure trans-
ducer, was greatest in the gluteus maximus, rectus
femoris, vastus medialis, vastus lateralis, tibialis anterior,
gastrocnemius and biceps femoris [21]. Our findings
confirmed that the greatest amount of perceived sore-
ness was reported during 24 and 48 hr following the
DHR with no differences between groups. Therefore, it
appears the selected intensity of running downhill at -5%
at 75% VO2max was a sufficient enough stimulus to elicit
muscle soreness as shown in other studies [6,22]. In an
attempt to reduce DOMS and stimulate protein synthe-
sis following strenuous exercise supplementation with
protein [22], BCAAs [9,23-25], leucine [2], and creatine
[11,26] have been used. Interestingly, acute ingestion of
protein (100 g of protein containing 40 g essential amino
acids) immediately after a single 30 min bout of DHR
had no effect on DOMS during 72 hr of recovery [22];
however supplementation with BCAAs (2.5 g of BCAAs
taken both immediately prior to- and during exercise)
significantly decreased DOMS from 24 to 72 hr post-
endurance exercise [9]. In the present study, no significant
difference in perceived soreness was reported between
groups, which agrees with others using protein [22],
BCAAs [10], leucine individually [2], or creatine [11,26].
The discrepancies could be due to higher individual dos-
ages of each individual supplement in previous studies
compared to our MIPS.
Biochemical markers of muscle damage
Our findings of elevated muscle damage markers (CK
and LDH) following eccentrically-based exercise support
previous research [3,27-29]. Although large variability
exists in the response of these muscle proteins to eccen-
tric exercise [30-32], the concurrent elevations in subse-
quent pain experienced (DOMS ratings) by participants
suggest the two are closely linked. Indeed, our findings
support this relationship as both mean perceived muscle
soreness (Table 2) and CK levels (Figure 2) were signifi-
cantly elevated POST, 24, and 48 hr post-DHR in com-
parison to PRE. In addition, LDH levels (Figure 3) were
significantly elevated POST and had a tendency to remainelevated up to 48 hr post-DHR. While the DHR protocol
induced muscle soreness and damage a MIPS did not
attenuate this response. Our findings agree with others
examining the eccentrically-induced CK response to
whey protein [5,8,22], BCAAs [10,33], leucine alone [2],
caffeine [14], and creatine [11,12], but not others show-
ing a reduction in CK as a result of creatine [12,34] or
BCAA supplementation [9,24,35]. Furthermore, our
findings corroborate the increased LDH response to
whey protein (1.5 g/kg/day of whey protein isolate for
14 days) [5] and caffeine (4.5 mg/kg immediately prior
to exercise) [14], but not the reduction of LDH as a re-
sult of BCAA supplementation (12 g/day of BCAAs for
14 days and an additional 20 g immediately prior to- and
post-exercise) [35]. Again, this is likely due to different
dosing of the individual ingredients within the propriety
blend of our MIPS and that of other studies as well as
differences in supplement timing and training status of
the participants in each study.
Performance measurements and range of motion
Decrements in performance measurements of strength
(isometric and isokinetic strength) [2,5,6,23], jump height
[2], and ROM [11,24,26] following eccentric exercise have
been well documented. Across groups, maximal isometric
strength was significantly lower at 24, 48, and 72 hr com-
pared to immediately post-DHR. Similarly, isokinetic ex-
tension strength decreased compared to baseline at 24 hr
post-DHR, returning back to baseline values at 48 hr.
Interestingly, isokinetic flexion strength actually improved
significantly in both groups at 48 and 72 hr post-DHR
compared to baseline, suggesting a possibility of familia-
rization with the equipment, and/or the absence of any
structural damage to the muscle fibers allowing strength
to be maintained and even improve throughout the recov-
ery period.
Etheridge et al. reported that participants supplement-
ing with whey protein (100 g of protein containing 40 g
essential amino acids) immediately after a single 30 min
bout of DHR had significantly greater isometric strength
at 48 hr compared to a carbohydrate supplement [22].
Controversy still exists as to whether BCAAs are effect-
ive in attenuating strength loss following EIMD. Some
studies have shown that BCAAs are only effective in
augmenting strength at 48 hr [9,25] after EIMD and only
during the flexion phase of the contraction [9] versus
placebo. Creatine also shows conflicting results for improv-
ing strength performance following EIMD. Despite our
findings and others that report no change in 1-repetition
maximum after EIMD with creatine use [11,26], Cooke
et al. have shown that maximal isometric extension
strength of the lower leg from 24 to 96 hr and isokinetic
extension strength at 48 hr was significantly greater in the
creatine supplementation group (0.3 g/kg/day) compared
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ences between studies appears to be differences in training
status as the present study and others [11,26] have shown
no effect of creatine supplementation with trained males,
while Cooke et al. have shown improvements in strength
following EIMD with untrained males [34]. Acute inges-
tion of protein prior to a single bout of DHR resulted in a
[22] maximal voluntary isometric contraction strength
that returned to normal more rapidly at 48 hr than that of
placebo. Our results do not support this conclusion with
the consumption of MIPS. Our findings agree with others
showing that BCAA consumption (7.3 g for two days) re-
sulted in no difference in maximal voluntary isometric
contraction strength during recovery from exercise [10].
However, the aforementioned study by Etheridge et al.
documented improvements in strength and power; though
the authors based the intensity of the DHR on age predic-
ted maximal heart rate (220 - age) and used recreationally
active males [22].
Jump height has been found to significantly decrease
at 24 and 48 hr following EIMD and remain below pre-
exercise values for up to 96 hr [2,23]. Similarly, our data
show decreased jump height at 24 hr following the DHR
compared to all other time points with a return back to
baseline values at 72 hr post-exercise, regardless of
group. Eccentric exercises have been shown to signifi-
cantly decrease maximal isometric contraction strength
from 24 up to 120 hr compared to baseline values
[5,6,9,10,22,23]. These decrements in strength from ec-
centric exercise are associated with a decreased ROM
immediately following [11,26] and up to 96 hr [24] after
exercise. ROM was slightly elevated immediately follow-
ing exercise in the present study, as documented by
others [12], but was significantly lower at 24 hr compared
to before the DHR and was back to baseline values at
72 hr (Table 3).
As previously mentioned, decreased ROM and strength
[11,26] are expected following EIMD. Our results also
found a decrease in ROM at 24 hr post-DHR with ROM
returning back to baseline values at 72 hr, with no
differences between groups. Similarly to the findings
of the present study, Nosaka et al. and Rawson et al.
demonstrated no improvement in ROM between sup-
plementation or placebo when consuming BCAAs [24] or
creatine [11,26].
One interesting finding from the present study was
the group x time interaction in VO2max over the 4-week
pre-loading period. The supplement group had an in-
crease in VO2max approaching significance at p = 0.064
and the CON group had a non-significant decrease in
VO2max. The 1.6 ml/kg/min increase likely does not rep-
resent a true physiological improvement. These findings
should be examined further in future research. Partici-
pants were asked not to change their training volumeover the 4-week supplementation period. While training
logs were not completed, verbal verification was ob-
tained to confirm that the participants did not alter their
training regimen. It is plausible that MIPS improved
training quality over the 4 weeks and that this was re-
sponsible for adaptations that improved aerobic capacity.
Therefore, MIPS may not improve performance in recov-
ery but rather impacts other indices of fitness in athletes.
However, this is all speculative.
Finally, it is important to note that the indirect
markers of muscle damage that were used in the present
study may have been limited in terms of their sensitivity,
and bias, to identify specific responses to the downhill
run and the effects of MIPS. This statement relates to a
recent alternative perspective on changes in skeletal
muscle in response to unaccustomed eccentric exercise
in humans [36-38]. Specifically, these authors argue that
the changes following voluntary eccentric exercise do
not represent muscle damage, muscle necrosis or inflam-
mation in human skeletal muscle but rather provide evi-
dence for myofibrillar remodeling and adaptation [36-38].
Further, the use of indirect measures and direct antibody
visualization of EIMD in previous studies, provides limited
and biased information in human eccentric exercise mo-
dels such as downhill running [36]. Rather, Malm and Yu
[36] suggest that researchers should use proteomics to
provide a powerful and unbiased protein profiling method
for studying skeletal muscle adaptation to eccentric exer-
cise. This is an important methodological issue to consider
for future studies.
Conclusions
Our results are consistent with others reporting increases
in perceived soreness, CK, LDH and decreases in strength,
vertical jump and ROM 24 hr after strenuous DHR exer-
cise. However, the use of a proprietary blend MIPS had no
effect on markers of muscle damage, soreness or per-
formance compared to an isocaloric placebo. Despite the
supporting body of research documenting results in the
attenuation of markers of muscle damage, soreness and
improved performance measurements with supplementa-
tion, other studies using protein, BCAAs, creatine, and
leucine reported similar results to ours. The primary dif-
ferences between our studies and those with contradicting
results appear to be greater individual supplementation
dosages than the proprietary blend of individual supple-
ments in the MIPS. In addition, we used trained male en-
durance runners compared to that of recreationally active
or untrained males in similar studies.
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